United Therapeutics (UTHR) Faces Yutrepia Pressure, Is It Still 29% Undervalued?
Liquidia’s push to broaden the use of Yutrepia in pulmonary arterial hypertension puts fresh attention on United Therapeutics (UTHR). The company’s inhaled treprostinil products already serve this market and shape competitive expectations for future patient share.
Recent trading has cooled, with the share price down 3.5% on the day, 5.0% over the past week and 8.9% across 30 days. Even so, United Therapeutics still carries an 11.0% one year total shareholder return and a very large 5 year total shareholder return of about 2.6x. This points to longer term momentum even as short term sentiment softens around competitive headlines like Liquidia’s Yutrepia push.
Compare United Therapeutics’ setup against hand-picked pulmonary and biotech peers by running through the 16 high quality undiscovered gems that could be quietly building similar long-term return potential.
Short-term pressure, long-term gains on the scoreboard. Does United Therapeutics’ recent pullback and strong multi-year record still leave enough upside in the risk-reward profile for new buyers at today’s price, once valuation is unpacked next?
Most Popular Narrative: 29% Undervalued
On the most followed narrative, United Therapeutics screens as meaningfully below an estimated fair value of $665.23 compared with the last close at $472.21. That gap hinges heavily on how far the pulmonary franchise can reach beyond pulmonary arterial hypertension.
The company's innovation wave pipeline, including studies in progressive fibrosis, next-generation delivery platforms (oral, implantable), and organ manufacturing (xenotransplant/3D printing), positions United Therapeutics to benefit from the expanding focus on personalized and regenerative medicine, which can create new revenue streams and margin expansion opportunities as these long-horizon technologies approach clinical milestones and eventual commercialization.
See why 31 investors see United Therapeutics as 29% undervalued.
Result: Fair Value of $665.23 (UNDERVALUED)
Still, the United Therapeutics narrative can crack if key pulmonary trials disappoint or if competitor treprostinil options pressure pricing power more quickly than expected.
Find out about the key risks to this United Therapeutics narrative.
Next Steps
If the United Therapeutics story so far sounds optimistic, treat it as a starting point and pressure test the numbers yourself. To see what those positives look like in detail, review the 4 key rewards.
Looking for more United Therapeutics investment ideas?
If United Therapeutics has sharpened your thinking, do not stop at one ticker. Use the Simply Wall Street Screener to surface fresh, data driven ideas tailored to how you like to invest.
- Target resilient balance sheets by reviewing the list of solid balance sheet and fundamentals (24 results) that pair healthy finances with fundamentals you can scrutinize in minutes.
- Hunt for quality at a discount through the 30 high quality undervalued stocks that surfaces stocks where fundamentals may not match the current price.
- Build a watchlist of potential future favorites by scanning the 16 high quality undiscovered gems that many investors might not yet be tracking closely.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com